Archives

D3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types

B Elisrasib monotherapy demonstrates notable efficacy in three major tumor types at its recommended phase 2 dose (RP2D, 600 mg QD). Phase 2 clinical outcomes… Login to continue reading Login…

Read MoreD3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types